OS Therapies Incorporated (OSTX)
ASE · Healthcare · Biotechnology
$1.68
-7.69%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$78.1M
Shares Outstanding
46.5M
Exchange
ASE
Currency
USD
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (6.9M) | (12.0M) | (10.2M) | (8.6M) |
| Net Income | (6.9M) | (13.5M) | (10.4M) | (8.6M) |
| Diluted EPS | $-0.21 | N/A | $-0.27 | $-0.20 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.4M) | (4.3M) | (6.8M) | (28.7M) |
| Net Income | (6.3M) | (7.8M) | (8.9M) | (28.8M) |
| Diluted EPS | $-0.32 | $-0.38 | $-1.28 | $-0.98 |